Samuel T Henderson

Summary

Publications

  1. ncbi Ketone bodies as a therapeutic for Alzheimer's disease
    Samuel T Henderson
    Accera, Inc, Broomfield, Colorado 80021, USA
    Neurotherapeutics 5:470-80. 2008
  2. ncbi Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study
    Samuel T Henderson
    Accera Inc, Broomfield, CO 80021, USA
    BMC Med Genet 12:137. 2011
  3. ncbi Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
    Samuel T Henderson
    Accera, Inc, 380 Interlocken Crescent, Suite 780, Broomfield, Colorado 80021, USA
    Nutr Metab (Lond) 6:31. 2009
  4. ncbi Hypometabolism as a therapeutic target in Alzheimer's disease
    Lauren C Costantini
    Accera Inc, Interlocken Crescent, Broomfield, CO 80021, USA
    BMC Neurosci 9:S16. 2008
  5. ncbi Effects of beta-hydroxybutyrate on cognition in memory-impaired adults
    Mark A Reger
    Accera, Inc, Aurora, CO 80010, USA
    Neurobiol Aging 25:311-4. 2004
  6. ncbi High carbohydrate diets and Alzheimer's disease
    Samuel T Henderson
    Accera Inc and Institute for Behavioral Genetics, University of Colorado, 1480 30th Street, Boulder, CO 80303, USA
    Med Hypotheses 62:689-700. 2004

Detail Information

Publications6

  1. ncbi Ketone bodies as a therapeutic for Alzheimer's disease
    Samuel T Henderson
    Accera, Inc, Broomfield, Colorado 80021, USA
    Neurotherapeutics 5:470-80. 2008
    ..Research into the therapeutic potential of KB and ketosis represents a promising new area of AD research...
  2. ncbi Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study
    Samuel T Henderson
    Accera Inc, Broomfield, CO 80021, USA
    BMC Med Genet 12:137. 2011
    ..To examine the effect of genetic variation in APOE, IDE and IL1B on the response to induced ketosis in the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in subjects with mild to moderate Alzheimer's disease (AD)...
  3. ncbi Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
    Samuel T Henderson
    Accera, Inc, 380 Interlocken Crescent, Suite 780, Broomfield, Colorado 80021, USA
    Nutr Metab (Lond) 6:31. 2009
    ..abstract:..
  4. ncbi Hypometabolism as a therapeutic target in Alzheimer's disease
    Lauren C Costantini
    Accera Inc, Interlocken Crescent, Broomfield, CO 80021, USA
    BMC Neurosci 9:S16. 2008
    ..Treatment outcomes were influenced by apolipoprotein E genotype status. These data suggest that AC-1202 may be an effective treatment for cognitive dysfunction by providing an alternative substrate for use by glucose-compromised neurons...
  5. ncbi Effects of beta-hydroxybutyrate on cognition in memory-impaired adults
    Mark A Reger
    Accera, Inc, Aurora, CO 80010, USA
    Neurobiol Aging 25:311-4. 2004
    ..02). Additional research is warranted to determine the therapeutic benefits of MCTs for patients with AD and how APOE-4 status may mediate beta-OHB efficacy...
  6. ncbi High carbohydrate diets and Alzheimer's disease
    Samuel T Henderson
    Accera Inc and Institute for Behavioral Genetics, University of Colorado, 1480 30th Street, Boulder, CO 80303, USA
    Med Hypotheses 62:689-700. 2004
    ..Interventions that restore lipid homeostasis may treat the disease, including drugs that increase fatty acid metabolism, EFA repletion therapy, and ketone body treatment...